These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21595883)

  • 1. Analysis and design of randomised clinical trials involving competing risks endpoints.
    Tai BC; Wee J; Machin D
    Trials; 2011 May; 12():127. PubMed ID: 21595883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating sample size in the presence of competing risks - Cause-specific hazard or cumulative incidence approach?
    Tai BC; Chen ZJ; Machin D
    Stat Methods Med Res; 2018 Jan; 27(1):114-125. PubMed ID: 26711503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
    Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
    Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the importance of accounting for competing risks in pediatric cancer trials designed to delay or avoid radiotherapy: I. Basic concepts and first analyses.
    Tai BC; Grundy RG; Machin D
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1493-9. PubMed ID: 19577860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empirical comparison of methods for analyzing multiple time-to-event outcomes in a non-inferiority trial: a breast cancer study.
    Parpia S; Thabane L; Julian JA; Whelan TJ; Levine MN
    BMC Med Res Methodol; 2013 Mar; 13():44. PubMed ID: 23517401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients.
    de Glas NA; Kiderlen M; Vandenbroucke JP; de Craen AJ; Portielje JE; van de Velde CJ; Liefers GJ; Bastiaannet E; Le Cessie S
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26614095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of censoring in competing risks analysis of the subdistribution hazard.
    Donoghoe MW; Gebski V
    BMC Med Res Methodol; 2017 Apr; 17(1):52. PubMed ID: 28376736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use and interpretation of competing risks regression models.
    Dignam JJ; Zhang Q; Kocherginsky M
    Clin Cancer Res; 2012 Apr; 18(8):2301-8. PubMed ID: 22282466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Planning and analyzing clinical trials with competing risks: Recommendations for choosing appropriate statistical methodology.
    Poythress JC; Lee MY; Young J
    Pharm Stat; 2020 Jan; 19(1):4-21. PubMed ID: 31625290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size calculations in the presence of competing risks.
    Latouche A; Porcher R
    Stat Med; 2007 Dec; 26(30):5370-80. PubMed ID: 17955563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size for a noninferiority clinical trial with time-to-event data in the presence of competing risks.
    Han D; Chen Z; Hou Y
    J Biopharm Stat; 2018; 28(4):797-807. PubMed ID: 29157093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons.
    Cantagallo E; De Backer M; Kicinski M; Ozenne B; Collette L; Legrand C; Buyse M; Péron J
    Biom J; 2021 Feb; 63(2):272-288. PubMed ID: 32939818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the relation between the cause-specific hazard and the subdistribution rate for competing risks data: The Fine-Gray model revisited.
    Putter H; Schumacher M; van Houwelingen HC
    Biom J; 2020 May; 62(3):790-807. PubMed ID: 32128860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fine-Gray subdistribution hazard models to simultaneously estimate the absolute risk of different event types: Cumulative total failure probability may exceed 1.
    Austin PC; Steyerberg EW; Putter H
    Stat Med; 2021 Aug; 40(19):4200-4212. PubMed ID: 33969508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical recommendations for reporting Fine-Gray model analyses for competing risk data.
    Austin PC; Fine JP
    Stat Med; 2017 Nov; 36(27):4391-4400. PubMed ID: 28913837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kidney Graft Failure and Patient Survival Modelling Based on Competing Risks Under Nonproportional Hazards.
    Valenta Z; Skrabaka D; Owczarek AJ; Kolonko A; Król R; Więcek A; Ziaja J
    Transplant Proc; 2022 May; 54(4):940-947. PubMed ID: 35450721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ignoring competing events in the analysis of survival data may lead to biased results: a nonmathematical illustration of competing risk analysis.
    Schuster NA; Hoogendijk EO; Kok AAL; Twisk JWR; Heymans MW
    J Clin Epidemiol; 2020 Jun; 122():42-48. PubMed ID: 32165133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Misspecified regression model for the subdistribution hazard of a competing risk.
    Latouche A; Boisson V; Chevret S; Porcher R
    Stat Med; 2007 Feb; 26(5):965-74. PubMed ID: 16755533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample sizes for clinical trials with time-to-event endpoints and competing risks.
    Schulgen G; Olschewski M; Krane V; Wanner C; Ruf G; Schumacher M
    Contemp Clin Trials; 2005 Jun; 26(3):386-96. PubMed ID: 15911472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.